Unlike regulators in the United States and Europe, the South African Health Products Regulatory Authority has not yet given the green light for any form of mix-and-match COVID-19 vaccine boosting. We take a look at the regulatory issues standing in the way of people in South Africa who received the Johnson & Johnson jab being offered Pfizer boosters.
Government can avoid the overwhelming of health services and minimise death in an anticipated fourth COVID-19 wave in November/December by getting 90% of people in South Africa over 35 years old vaccinated before then. Life could then return to normal by Christmas, even with ongoing SARS-CoV-2 circulation, contends vaccinologist Professor Shabir Madhi.
The new and more contagious Delta variant has now surpassed the Beta variant to become the dominant SARS-CoV-2 variant in South Africa. Laura Lopez Gonzalez pulled together answers to eight common questions asked about this new variant.
The two vaccines used in South Africa’s vaccination programme, those from Johnson & Johnson and Pfizer/BioNTech, have both been shown to be highly effective against COVID-19, particularly in preventing hospitalisation and death. But protection may wane over time and new variants may or may not render these vaccines less effective. Adele Baleta unpacks what we do and do not know about the potential need for booster shots and surveys some of the studies that will help fill the gaps.